 Updated Business Strategy Focused on Small Molecule Therapeutics Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic business for USD 5M Subject to Kedrion exercising said option, Liminal could receive up to 70 of net proceeds from sale of Priority Review Voucher for which it is potentially eligible with possible FDA approval for Ryplazim PDUFA Target Action Date of June 5, 2021 for Ryplazim plasminogen BLA Submission LAVAL, QC and CAMBRIDGE, England, May 17, 2021 PRNewswire - Liminal BioSciences Inc. Nasdaq: LMNL Liminal BioSciences or the Company, a clinical-stage biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2021. Liminal will host a conference call at 8:30 am ET on Tuesday May 18, 2021. 